Copenhagen - Free Realtime Quote DKK

BioPorto A/S (BIOPOR.CO)

1.6078

+0.0178

+(1.12%)

As of 9:51:30 AM GMT+2. Market Open.

Grant of Warrants

April 28, 2025Announcement no. 14 Grant of Warrants Copenhagen, Denmark, April 28, 2025, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has today implemented the resolution of the annual general meeting held on April 11, 2025 to issue a total of 1,700,000 warrants as part of the remuneration to members of the Board of Directors of the Company. Each warrant entitles the holder the right to subscribe for one share in BioPorto at an exercise pri

GlobeNewswire 7 days ago

THOXF
BioPorto A/S to host first quarter 2025 earnings webcast for investors

April 28, 2025 News release BioPorto A/S to host first quarter 2025 earnings webcast for investors COPENHAGEN, DENMARK, April 28, 2025 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today that, in connection with the release of its Interim Report for the first quarter 2025, CFO Niels Høy Nielsen will present financial results for Q1 2025 at a webcast for inve

GlobeNewswire 7 days ago

THOXF
BioPorto announces completion of an oversubscribed directed offering of 25 million new shares raising DKK 33.5 million

News Release April 25, 2025 BioPorto announces completion of an oversubscribed directed offering of 25 million new shares raising DKK 33.5 million COPENHAGEN, DENMARK, April 25, 2025 (GLOBE NEWSWIRE) – BioPorto, an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today the completion of a directed share capital raise of 25,000,000 new shares at the market offer price of DKK 1.3402 per share raising gross proceeds of DKK 33,505,000 mil

GlobeNewswire 10 days ago

THOXF
Managers’ transactions

April 25, 2025Announcement no. 13 Managers’ transactions In connection with the completion of BioPorto A/S’ directed issue as described in company announcement no. 12, BioPorto A/S has received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in BioPorto A/S made by persons discharging managerial responsibilities in BioPorto A/S and/or persons closely associated with them. 1 Details of the person discharging managerial responsibiliti

GlobeNewswire 10 days ago

THOXF
BioPorto A/S raises DKK 33.5 million in new capital round - Change of number of shares and votes

April 25, 2025Announcement no. 12 BioPorto A/S raises DKK 33.5 million in new capital round - Change of number of shares and votes Completion of share capital increase COPENHAGEN, DENMARK, April 25, 2025 (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), decided on April 15, 2025, to complete a private placement of 25,000,000 new shares to exi

GlobeNewswire 10 days ago

THOXF
Correction: Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S

April 15, 2025Announcement no. 11 Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S Copenhagen, Denmark, April 15, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announces that the private placement of 25,000,000 new shares has been completed. The initiation of the private placement was announced

GlobeNewswire 21 days ago

THOXF
Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S

April 15, 2025Announcement no. 11 Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S Copenhagen, Denmark, April 15, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announces that the private placement of 25,000,000 new shares has been completed. The initiation of the private placement was announced

GlobeNewswire 21 days ago

THOXF
BioPorto A/S initiates a private placement of up to 25,000,000 new shares at market price. The Board of Directors has received advance indications for the full offering which is expected to raise proceeds of DKK 33.5 million.

April 14, 2025Announcement no. 10 THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE A PROSPECTUS OR A PUBLIC OFFER OF THE SECURITIES DESCRIBED HEREIN NOR IS IT AN OFFER TO SELL OR ISSUE, OR A SOLICITATION O

GlobeNewswire 21 days ago

THOXF
Resolutions of the Annual General Meeting

April 11, 2025 Announcement no. 9 Resolutions of the Annual General Meeting COPENHAGEN, DENMARK and BOSTON, MA, USA, April 11, 2025, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH: BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), today held its Annual General Meeting with the following results: Item 1 - The Board's report on the Company’s activities during the past year was noted by the Annual General Meeting. Item 2 –

GlobeNewswire 24 days ago

THOXF
Updated biographies for board candidates at the upcoming Annual General Meeting

1 April 2025Announcement no. 8 Updated biographies for board candidates at the upcoming Annual General Meeting Copenhagen, Denmark, April 1, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announces updated biographies for the candidates nominated for election as board members at the upcoming Annual General Meeting on 11 April,2025. On 25 March 2025 the Company publis

GlobeNewswire last month

THOXF
Notice convening the Annual General Meeting in BioPorto A/S

20 March 2025Announcement no. 7 Notice convening the Annual General Meeting in BioPorto A/S The Board of Directors hereby convenes the Annual General Meeting of BioPorto A/S (“BioPorto” or the “Company”) to be held on: 11 April 2025 at 3.00 p.m. (CEST)At the Company’s addressTuborg Havnevej 15, st., DK-2900 Hellerup, Denmark AGENDA: ITEM 1 - REPORT ON THE COMPANY’S ACTIVITIES DURING THE PAST YEAR The Board of Directors proposes that the Board's report on the Company’s activities for the past yea

GlobeNewswire last month

THOXF
BioPorto announces the Annual Report for 2024

March 20, 2025Announcement no. 06 BioPorto announces the Annual Report for 2024 Copenhagen, Denmark, March 20, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), today announces the annual financial results for 2024. Peter Mørch Eriksen, BioPorto’s Group Chief Executive Officer (CEO), comments It is with great enthusiasm that I reflect on the remarkable milestones achiev

GlobeNewswire last month

THOXF
BioPorto announces guidance for 2025 and aspirations for 2026 towards 2029

March 19, 2025Announcement no. 05 BioPorto announces guidance for 2025 and aspirations for 2026 towards 2029 Copenhagen, Denmark, March 19, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announces guidance for 2025 and aspirations for 2026 towards 2029. For 2025, BioPorto is targeting total revenue of DKK 45-60 million, corresponding to a growth in the range of 24-66

GlobeNewswire last month

THOXF
BioPorto A/S announces Jens Due Olsen as a Board of Directors candidate intending to appoint Jens Due Olsen as Chair, along with updates on other candidates

March 4, 2025Announcement no. 04 BioPorto A/S announces Jens Due Olsen as a Board of Directors candidate intending to appoint Jens Due Olsen as Chair, along with updates on other candidates COPENHAGEN, DENMARK, March 4, 2025 – BioPorto A/S (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announces Jens Due Olsen as a board candidate with the intention of appointing Jens Due Olsen as Chair of the Board of Directors following the

GlobeNewswire 2 months ago

THOXF
Strengthening of Investor Focus – BioPorto enters Market Maker Agreement with Danske Bank & appoints New Head of Investor Relations

February 27, 2025Announcement no. 03 Strengthening of Investor Focus – BioPorto enters Market Maker Agreement with Danske Bank & appoints New Head of Investor Relations COPENHAGEN, DENMARK, February 27, 2025, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no. 17500317 (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), today announced that it has entered into a Market Maker Agreement with Danske Bank and appoints Hanne

GlobeNewswire 2 months ago

THOXF
BioPorto A/S appoints new interim Chairman of the Board

January 29, 2025Announcement no. 02 BioPorto A/S appoints new interim Chairman of the Board COPENHAGEN, DENMARK, January 29, 2025, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no. 17500317 (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), today announced that Board Member Henrik Juuel will be appointed interim Chairman of the Board of Directors in BioPorto A/S as John McDonough steps down and resigns as Chair and me

GlobeNewswire 3 months ago

THOXF
BioPorto announces the publication of urinary NGAL reference ranges in healthy adult and pediatric individuals

News Release January 23, 2025 BioPorto announces the publication of urinary NGAL reference ranges in healthy adult and pediatric individuals COPENHAGEN, DENMARK, January 23, 2025 (GLOBE NEWSWIRE) – BioPorto, an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today their publication of reference intervals using BioPorto’s NGAL immunoassay in healthy adult and pediatric individuals. The study was published in Diagnostics, an internatio

GlobeNewswire 3 months ago

THOXF
Preliminary Financial Figures for the 2024 Fiscal Year

January 6, 2025 Announcement no. 01 Preliminary Financial Figures for the 2024 Fiscal Year COPENHAGEN, DENMARK, January 6, 2025, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no. 17500317 (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), today announced preliminary financial figures for financial year 2024. Preliminary Financial Figures for the 2024 Financial Year The revenue for the 2024 financial year was DKK 36.2

GlobeNewswire 3 months ago

THOXF
BioPorto commences process to appoint new Chair of the Board of Directors

December 16, 2024 Announcement no. 23 BioPorto commences process to appoint new Chair of the Board of Directors COPENHAGEN, DENMARK, December 16, 2024 (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) today announces that it has commenced a search and nomination process for a new Chair of the Board of Directors. The current Chair of the Board, John McDonough, has decided he will resign no later than at the upcoming annual general meeting. John McDonough

GlobeNewswire 4 months ago

THOXF
BioPorto Announces Interim Results and Business Update for the Third Quarter and Nine Months of Fiscal 2024

November 14, 2024Announcement no. 22 BioPorto Announces Interim Results and Business Update for the Third Quarter and Nine Months of Fiscal 2024 Revenue growth and strategic execution COPENHAGEN, Denmark, November 14, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S CVR-no. 17500317 (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), today announced interim financial results for the first nine months of 2024 and busine

GlobeNewswire 5 months ago

THOXF

Performance Overview

Return	BIOPOR.CO	OMX Copenhagen 25 Index (^OMXC25)
YTD	+3.73%	-4.24%
1-Year	+10.12%	-9.87%
3-Year	+33.74%	-1.12%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioPorto A/S (BIOPOR.CO)

Grant of Warrants

BioPorto A/S to host first quarter 2025 earnings webcast for investors

BioPorto announces completion of an oversubscribed directed offering of 25 million new shares raising DKK 33.5 million

Managers’ transactions

BioPorto A/S raises DKK 33.5 million in new capital round - Change of number of shares and votes

Correction: Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S

Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S

BioPorto A/S initiates a private placement of up to 25,000,000 new shares at market price. The Board of Directors has received advance indications for the full offering which is expected to raise proceeds of DKK 33.5 million.

Resolutions of the Annual General Meeting

Updated biographies for board candidates at the upcoming Annual General Meeting

Notice convening the Annual General Meeting in BioPorto A/S

BioPorto announces the Annual Report for 2024

BioPorto announces guidance for 2025 and aspirations for 2026 towards 2029

BioPorto A/S announces Jens Due Olsen as a Board of Directors candidate intending to appoint Jens Due Olsen as Chair, along with updates on other candidates

Strengthening of Investor Focus – BioPorto enters Market Maker Agreement with Danske Bank & appoints New Head of Investor Relations

BioPorto A/S appoints new interim Chairman of the Board

BioPorto announces the publication of urinary NGAL reference ranges in healthy adult and pediatric individuals

Preliminary Financial Figures for the 2024 Fiscal Year

BioPorto commences process to appoint new Chair of the Board of Directors

BioPorto Announces Interim Results and Business Update for the Third Quarter and Nine Months of Fiscal 2024

Performance Overview